Recent performance snapshot

Novavax (NVAX) has drawn fresh attention after a period where the stock rose around 31% over the past month and about 11% over the past 3 months, in the context of ongoing vaccine commercialization.

That recent 30.7% 1 month share price return builds on a 47.4% year to date share price gain and a 48.7% 1 year total shareholder return, although the 5 year total shareholder return remains sharply negative at 94.6%.

If you are comparing Novavax with other opportunities in healthcare and biotech, it can be useful to see which smaller players are attracting attention, starting with 40 healthcare AI stocks

With the stock up strongly over the past year, trading at $10.51 and sitting below an average analyst price target of $14.11, the key question is whether Novavax still looks undervalued or if the market is already pricing in future growth.

Most Popular Narrative: 24% Undervalued

With Novavax last closing at $10.51 against a narrative fair value estimate of $13.78, the most followed view sees meaningful upside still on the table.

The license agreement with Pfizer, including a US$30m upfront payment and high mid single digit royalties on products containing Matrix M, adds a defined cash inflow and a potential recurring royalty stream that can support enterprise value beyond the core COVID vaccine business.

Want to know what kind of revenue reset and margin profile could justify that fair value, even with declining top line assumptions baked in? The full narrative outlines how shrinking revenues, changing profit margins and a richer future earnings multiple intersect to arrive at that $13.78 figure.

Result: Fair Value of $13.78 (UNDERVALUED)

However, you still need to weigh the heavy dependence on partner driven royalties and COVID related vaccines. Weaker uptake or regulatory setbacks could quickly challenge that undervalued thesis.

Next Steps

The mixed tone of this story, with both risks and potential rewards in play, means the next move is on you. Take a closer look at the details and pressure test the assumptions that matter most for your portfolio, starting with 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If Novavax sits on your watchlist, do not stop there. Cast the net wider and compare it with other focused opportunities before you commit fresh capital.

• Target resilience by checking out companies screened for stronger balance sheets and fundamentals through the solid balance sheet and fundamentals stocks screener (45 results).
• Hunt for potential mispricing by reviewing the 47 high quality undervalued stocks and see which stocks currently trade below their assessed worth.
• Prioritise consistency by scanning income focused opportunities through the 10 dividend fortresses that highlight higher yielding dividend payers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.